



Conference Abstract


<http://dx.doi.org/10.21065/19204159.pharm.alazhar>

A Response to COVID-19

International Conference of Pharmaceutical and Medical Sciences

September 1-3, 2020 (Tuesday - Thursday)

Faculty of Pharmacy For Girls - Al Azhar University, Cairo, Egypt.



Conference Abstract

COVID-19 WORLDWIDE

Hala Adly Hussein

Federation of Arab Women Leaders Hay Al 304. Zuqaq 5/33. Baghdad, Iraq

ABSTRACT

The current China virus, commonly known as novel coronavirus, has, however, never been encountered before, and that is why it has caught the attention of the world. There are no vaccines or antiviral drugs to prevent or treat human coronavirus infections. There are many traditional herbs that can control the infection in addition to bee venom. Globally drugs used for treatment include Hydroxy chloroquine, favipiravir, remdesivir, sofosbuvir, daclatasvir, ivermectin & dexamethasone. Treatment base of any virus include immune control drugs, immune regulator, protective drugs and symptomatic treatment. Developing vaccine against COVID-19 takes from 18 -24 months so clinical trial started in parallel pathway..

Speaker's Biography

The Secretary-General of Federation of Arab Women Leaders affiliated with the Joint Arab Labor System of the League of Arab States. Chairman for Bio Misr for pharmaceutical Industries Company. Chairman for Mica Pharma Company. Former Chairman and CEO of EGYVAC (Vacsera). Former General Manager of Amoun Pharmaceutical Company. Former General Manager of the development department of the Pharco Pharmaceutical Group. Lecturer in the faculty of pharmacy El-Mansoura University. Member of the National Council for Women (2001-2011). MBA in business Administration. Rapporteur of the Women's Unit Environment's Affairs system (Delta East) till 2011. Member of the Women faith committee in COPPEM (Committee Euro Mediterranean Partnership of Local and Regional Authorities). Member of the National Council for Women (2001-2011).

Corresponding author:

Hala Adly Hussein Federation of Arab Women Leaders Hay Al Maghreb. Maheala 304. Zuqaq 5/33. Baghdad, Iraq
E: islam.anan@accsight.com

Citation:

Hala Adly Hussein. Covid – 19 Worldwide. J App Pharm. Volume. Vol. 12: 2020. Special Issue 1st International Conference of Pharmaceutical and Medical Sciences; A Response to COVID-19. September 1-3, 2020: Faculty Of Pharmacy For Girls - Al Azhar University, Cairo, Egypt.

Funding:

The authors received no direct funding for this research.

Competing Interests:

The authors declare no competing interest's

Additional information is available
at the end of the article.

Ethics approval and consent to participate: No ethical approval needed for this research work.

Ethics approval and consent to participate: No ethical approval needed for this research work.

Consent for publication: Author is agreed to submit this abstract for publication in this research journal.

Availability of data and materials: The information and data collected and/ or incorporated in this study is included in this manuscript.

Declaration: The abstract is reviewed and accepted by the Conference Organization Committee of the event entitled "A Response to COVID-19: International Conference of Pharmaceutical and Medical Sciences" dated September 1-3, 2020 (Tuesday - Thursday), held at Faculty Of Pharmacy For Girls - Al Azhar University, Cairo, Egypt. The presenter was permitted to share his research after final approval of the committee. The scientific information and data is published on behalf of the Conference organization Committee.



© 2020 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.

You are free to: Share — copy and redistribute the material in any medium or format. Adapt - remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:

Attribution - You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.